Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 5, 2012, Pages 1493-1499

  Jang, Joanne W ^a   Hwang, Wei Ting ^b   Guzzo, Thomas J ^b   Wein, Alan J ^b   Haas, Naomi B ^b   Both, Stefan ^a   Vapiwala, Neha ^a  

^a Pzerelman Center for Advanced Medicine   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Androgen deprivation therapy; Biochemical recurrence; Prostate cancer; Salvage radiation therapy

Indexed keywords

ANTIGENS; DISEASES; PATHOLOGY; RADIOTHERAPY;

ANDROGEN DEPRIVATION THERAPY; BIOCHEMICAL RECURRENCE; EXTERNAL BEAM RADIATION THERAPY; METHODS AND MATERIALS; PROGRESSION FREE SURVIVAL; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; SALVAGE RADIATION THERAPIES;

UROLOGY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ANDROGEN DEPRIVATION THERAPY; BIOCHEMISTRY; CANCER INVASION; CANCER RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; LYMPH NODE IRRADIATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PELVIS LYMPH NODE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SALVAGE THERAPY; SEMINAL VESICLE; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES;

EID: 84863618812     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.10.047     Document Type: Article

References (28)

1. Cancer Facts & Figures 2010 2010 American Cancer Society
2. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974
3. M. Han, A.W. Partin, and S. Piantadosi Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer J Urol 166 2001 416 419
4. M. Han, A.W. Partin, and C.R. Pound Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience Urol Clin North Am 28 2001 555 565
5. M. Han, A.W. Partin, and M. Zahurak Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer J Urol 169 2003 517 523
6. C.R. Pound, A.W. Partin, and M.A. Eisenberger Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
7. D. Pasquier, and C. Ballereau Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: A literature review Int J Radiat Oncol Biol Phys 72 2008 972 979
8. A.J. Stephenson, S.F. Shariat, and M.J. Zelefsky Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy JAMA 291 2004 1325 1332
9. M. Bolla, H. van Poppel, and L. Collette Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911) Lancet 366 2005 572 578
10. I.M. Thompson Jr. , C.M. Tangen, and J. Paradelo Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial JAMA 296 2006 2329 2335
11. G.P. Swanson, and I.M. Thompson Adjuvant radiotherapy for high-risk patients following radical prostatectomy Urol Oncol 25 2007 515 519
12. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A Phase III randomised trial Lancet 360 2002 103 106
13. A.V. D'Amico, J. Manola, and M. Loffredo 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial JAMA 292 2004 821 827
14. J.W. Denham, A. Steigler, and D.S. Lamb Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial Lancet Oncol 6 2005 841 850
15. G.E. Hanks, T.F. Pajak, and A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 21 2003 3972 3978
16. J. Laverdiere, A. Nabid, and L.D. De Bedoya The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer J Urol 171 2004 1137 1140
17. M.V. Pilepich, K. Winter, and M.J. John Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252
18. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of Phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290
19. M. Roach 3rd, M. DeSilvio, and C. Lawton Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 J Clin Oncol 21 2003 1904 1911
20. Shipley WS, Hunt D, Lukka H, et al. Initial Report of RTOG 9601: A Phase III Trial in Prostate Cancer: Anti-androgen Therapy (AAT) with Bicalutamide during and after Radiation Therapy (RT) Improves Freedom from Progression and Reduces the Incidence of Metastatic Disease in Patients following Radical Prostatectomy (RP) with pT2-3, N0 Disease, and Elevated PSA Levels. Presented at the ASTRO annual conference, San Diego, CA; 2010.
21. Parker C. Radiation therapy and androgen deprivation therapy in treating patients who have undergone surgery for prostate cancer (RADICALS). Randomized trial currently in accrual: http://clinicaltrials.gov/ct2/show/NCT00541047. Accessed Febraury 09, 2011.
22. Pollack A. A Phase III trial of short term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy (SPPORT) in prostate cancer patients with a rising PSA after radical prostatectomy. Randomized trial currently in accrual: http://clinicaltrials.gov/ct2/show/NCT01312974. Accessed Febraury 09, 2011.
23. S.M. Eulau, D.J. Tate, and T.A. Stamey Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer Int J Radiat Oncol Biol Phys 41 1998 735 740
24. C.R. King, J.C. Presti Jr. , and H. Gill Radiotherapy after radical prostatectomy: Does transient androgen suppression improve outcomes? Int J Radiat Oncol Biol Phys 59 2004 341 347
25. D.E. Soto, M.N. Passarelli, and S. Daignault Concurrent androgen deprivation therapy during salvage prostate radiotherapy improves treatment outcomes in high-risk patients Int J Radiat Oncol Biol Phys 2011 In press
26. B.J. Trock, M. Han, and S.J. Freedland Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy JAMA 299 2008 2760 2769
27. R. Cheung, A.M. Kamat, and R. De Crevoisier Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy Int J Radiat Oncol Biol Phys 63 2005 134 140
28. M.S. Katz, M.J. Zelefsky, and E.S. Venkatraman Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer J Clin Oncol 21 2003 483 489